Filgotinib improved endo-histological outcomes in patients with UC, with a dose-dependent effect on transcription. Gene expression changes and enriched pathways suggest that achieving endoscopic and histological endpoints in patients receiving FIL was associated with the restoration of mucosal homeostasis.
Magro et al. (Thu,) studied this question.